Advanced search
Publication Cover
Upsala Journal of Medical Sciences Volume 122, 2017 - Issue 3
Journal homepage
1,252
Views
5
CrossRef citations to date
0
Altmetric
Original Article

A novel prothrombin time method to measure all non-vitamin K-dependent oral anticoagulants (NOACs)

Tomas L. LindahlDepartment of Clinical Chemistry, Linköping University, Linköping, Sweden; ;Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; Correspondence[email protected]
View further author information
,
Kerstin ArbringDepartment of Acute Internal Medicine, Linköping University, Linköping, Sweden; ;Department of Medical and Health Sciences, Linköping University, Linköping, Sweden; View further author information
,
Maria WallstedtDepartment of Clinical Chemistry, Linköping University, Linköping, Sweden; ;Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden; View further author information
&
Mats RånbyZafena AB, Borensberg, SwedenView further author information
Pages 171-176 | Received 27 Mar 2017, Accepted 16 Aug 2017, Published online: 11 Sep 2017

References

  • Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63:321–8.
  • Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62.
  • Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–51.
  • Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943–51.
  • Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest. 1951;3:201–8.
  • Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med. 1997;127:177–85.
  • Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371–8.
  • Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133–9.
  • Hillarp A, Gustafsson KM, Faxalv L, Strandberg K, Baghaei F, Fagerberg Blixter I, et al. Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays. J Thromb Haemost. 2014;12:1545–53.
  • Lindahl TL, Egberg N, Hillarp A, Odegaard OR, Edlund B, Svensson J, et al. INR calibration of Owren-type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples. Thromb Haemost. 2004;91:1223–31.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.